Tacrolimus but not cyclosporine A enhances FGF-2-induced VEGF release in osteoblasts

International Journal of Molecular Medicine

Volumn 23, Issue 2, 2009, Pages 267-272

  Yamauchi, Junichi ^a   Takai, Shinji ^a   Matsushima Nishiwaki, Rie ^a   Adachi, Seji ^a   Minamitani, Chino ^a,b   Natsume, Hideo ^a,b   Mizutani, Jun ^b   Otsuka, Takanobu ^b   Takeda, Jun ^c   Harada, Atsushi ^c   Kozawa, Osamu ^a   Tokuda, Harahiko ^a,c  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

c Jun N terminal kinase; Fibroblast growth factor 2; Osteoblast; p70 S6 kinase; Tacrolimus; Vascular endothelial growth factor

Indexed keywords

CYCLOSPORIN A; FIBROBLAST GROWTH FACTOR 2; S6 KINASE; STRESS ACTIVATED PROTEIN KINASE; TACROLIMUS; VASCULOTROPIN; CYCLOSPORIN; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; BONE METABOLISM; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; IMMUNOMODULATION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; GENETICS; METABOLISM; UPREGULATION;

ANIMALS; CELLS, CULTURED; CYCLOSPORINE; ENZYME INHIBITORS; FIBROBLAST GROWTH FACTOR 2; IMMUNOSUPPRESSIVE AGENTS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; OSTEOBLASTS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TACROLIMUS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 64749113307     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000126     Document Type: Article

References (31)

1. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
2. Nijweide PJ, Burger EH and Feyen JHM: Cells of bone: proliferation, differentiation, and hormonal regulation. Physiol Rev 86: 855-886, 1986.
3. Brighton CT and Hunt RM: Early histological and ultrastructural changes in medullary fracture callus. J Bone Joint Surg Am 73: 832-847, 1991.
4. Parfitt AM: Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 55: 273-286, 1994.
5. Erlebacher A, Filvaroff EH, Gitelman SE and Derynck R: Toward a molecular understanding of skeletal development. Cell 80: 371-378, 1995.
6. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z and Ferrara N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5: 623-628, 1999.
7. Goad DL, Rubin J, Wang H, Tashijian AH Jr and Patterson C: Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137: 2262-2268, 1996.
8. 3 in human osteoblast-like cells. J Bone Miner Res 11: 472-479, 1996.
9. Schalaeppi JM, Gutzwiller S, Finlenzeller G and Fournier B: 1,25-dihydroxyvitamin D3 induces the expression of vascular endothelial growth factor in osteoblastic cells. Endocr Res 23: 213-229, 1997.
10. Zelzer E and Olsen BR: Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. Curr Top Dev Biol 65: 169-187, 2005.
11. Baylink DJ, Finkleman RD and Mohan S: Growth factor to stimulate bone formation. J Bone Miner Res 8: S565-S572, 1993.
12. Hurley MM, Abreu C, Harrison JR, Lichtler AC, Raisz LG and Kream BE: Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3-E1 cells. J Biol Chem 268: 5588-5593, 1993.
13. Bolander ME: Regulation of fracture repair by growth factors stimulate tyrosine kinase activity in vivo. Proc Soc Exp Biol Med 200: 165-170, 1992.
14. Mari PJ: Fibroblast growth factor signaling controlling osteoblast differentiation. Gene 316: 23-32, 2003.
15. Suzuki A, Shinoda J, Kanda S, Oiso Y and Kozawa O: Basic fibroblast growth factor stimulates phosphatidylcholine-hydrolyzing phospholipase D in osteoblast-like cells. J Cell Biochem 63: 491-499, 1996.
16. Tokuda H, Kozawa O and Uematsu T: Basic fibroblast growth factor stimulates vascular endothelial growth factor release in osteoblasts: divergent regulation by p44/p42 mitogen-activated protein kinase and p38 mitogen-activated protein kinase. J Bone Miner Res 15: 2371-2379, 2000.
17. Tokuda H, Hirade K, Wang X, Oiso Y and Kozawa O: Involvement of SAPK/JNK in basic fibroblast growth factor-induced VEGF release in osteoblasts. J Endocrinol 177: 101-107, 2003.
18. Kyriakis JM and Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869, 2001.
19. Takai S, Tokuda H, Hanai Y, Harada A, Yasuda E, Matsushima-Nishiwaki R, Kato H, Ogura S, Ohta T and Kozawa O: Negative regulation by p70 S6 kinase of FGF-2-stimulated VEGF release through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. J Bone Miner Res 22: 337-346, 2007.
20. Wiederrecht G, Lam E, Hung S, Martin M and Sigal N: The mechanism of action of FK506 and cyclosporine A. Ann NY Acad Sci 696: 9-19, 1993.
21. Spencer CM, Goa KL and Gillis JC: Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54: 925-975, 1997.
22. Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WS and Epstein S: The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 57: 1231-1237, 1994.
23. Park KM, Hay JE, Lee SG, Lee YJ, Wiesner RH, Porayko MK and Krom RA: Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. Transplant Proc 28: 1738-1740, 1996.
24. Yoshikawa T, Nakajima H, Yamada E, Akahane M, Dohi Y, Ohgushi H, Tamai S and Ichijima K: In vivo osteogenic capability of cultured allogeneic bone in porous hydroxyapatite: immunosuppressive and osteogenic potential of FK506 in vivo. J Bone Miner Res 15: 1147-1457, 2000.
25. Yoshikawa T, Nakajima H, Uemura T, Kasai T, Enomoto Y, Tamura T, Nonomura A and Takakura Y: In vitro bone formation induced by immunosuppressive agent tacrolimus hydrate (FK506). Tissue Eng 11: 609-617, 2005.
26. Sudo H, Kodama H, Amagai Y, Yamamoto S and Kasai S: In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 96: 191-198, 2003.
27. 2 in osteoblast-like cells. Exp Cell Res 198: 130-134, 1992.
28. Laemmli LK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
29. Kato K, Ito H, Hasegawa K, Inaguma Y, Kozawa O and Asano T: Modulation of the stress-induced synthesis of hsp27 and alpha B-crystallin by cyclic AMP in C6 rat glioma cells. J Neurochem 66: 946-950, 1996.
30. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM and Anderson DW: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98: 13681-13686, 2001.
31. Tang L, Ebara S, Kawasaki S, Wakabayashi S, Nikaido T and Takaoka K: FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol Int 26: 75-84, 2002.